Recommendations for HLA‐B15:02 and HLA‐A31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions

• Published in: Epilepsia (Copenhagen) Vol. 55; no. 4; pp. 496 - 506
• Main Authors: Amstutz, Ursula, Shear, Neil H., Rieder, Michael J., Hwang, Soomi, Fung, Vincent, Nakamura, Hidefumi, Connolly, Mary B., Ito, Shinya, Carleton, Bruce C.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.04.2014
• Subjects: Anticonvulsants - adverse effects; Carbamazepine - adverse effects; Clinical medicine; Drug Hypersensitivity - diagnosis; Drug Hypersensitivity - genetics; Drug‐induced hypersensitivity syndrome; Genetic Markers - genetics; Genetic Testing - methods; HLA-A Antigens - genetics; HLA-B15 Antigen - genetics; Humans; Maculopapular exanthema; Medical research; Pharmacogenetic testing; Rash; Risk Factors; Stevens‐Johnson syndrome; Toxic epidermal necrolysis; Drug-induced hypersensitivity syndrome; Stevens-Johnson syndrome; Toxic epidermal necrolysis; Rash; Pharmacogenetic testing; Maculopapular exanthema

Summary Objective To systematically review evidence on genetic risk factors for carbamazepine (CBZ)–induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA‐B*15:02 and HLA‐A*31:01 be performed in patients with an...